12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Custirsen sodium: Updated Phase II data

Updated data from a North American Phase II trial in 82 patients showed that patients receiving IV OGX-011 plus docetaxel and prednisone had a median overall survival of 23.8 months compared with 16.9 months in patients receiving docetaxel and prednisone alone. Stable disease was observed in 20 patients in...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >